Stiftung Krankenhaus Bethanien Fuer Die Grafschaft Moers — Clinical Trial Site

17 Registered trials

13 Currently recruiting

Organisation

Stiftung Krankenhaus Bethanien Fuer Die Grafschaft Moers

Location

Moers, Germany

Identifier

ORG-100048799

Address

Bethanienstrasse 21, Innenstadt, 47441, Germany

Departments

2604 : Lungenkrebszentrum Moers
2610:Medizinische Klinik III
Ambulanz thorakale Onkologie
Klinik für Gastroenterologie und Onkologie
Klinik für Lungen- & Bronchialheilkunde
Lungen- & Bronchialheilkunde
Lungen- & Thoraxzentrum Nordrhein
Medizinische Klinik III, Pneumologie
Oncology
Oncoloy
Stifung Krankenhaus Bethanien Für Die Grafschaft Moers
Studienzentrum

Clinical trials at this site (17)

Search interface

A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung can… Recruiting

2025-522437-65-00 small-cell lung cancer 4 2026-03-06
A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici… Recruiting

2024-516792-32-01 Metastatic non-squamous non-small cell lung cancer 4 2025-07-18
Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin… Recruiting

2024-518210-81-00 Advanced Hepatocellular Carcinoma 5 2026-03-18
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant… Recruiting

2024-516794-70-00 Metastatic non-squamous non-small cell lung cancer 4 2025-11-03
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting

2023-509571-16-00 Lung Cancer 3 2024-07-17
A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting

2023-509572-42-00 Lung Cancer 3 2024-07-17
Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting

2023-508178-27-00 Participants with Advanced KRASG12C-Mutated Solid Tumor 9 2024-07-10
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 5 2024-03-20
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Gastric cancer, Advanced/Metastatic Gastric cancer, Gas 5 2025-01-17
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam… Ended

2023-507448-36-00 Non-small Cell Lung Cancer 5 2024-02-16
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03